CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?

Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma (NHL) and is highly invasive, with a poor prognosis. The main clinical treatment for DLBCL involves chemotherapy or a combination of chemotherapy and targeted drugs. CD56 expression is considered as an indicator of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanquan, Shen, Jianzhen, Awal Issah, M., Liu, Tingbo, Zhou, Huarong, Fu, Haiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218936/
https://www.ncbi.nlm.nih.gov/pubmed/32363958
http://dx.doi.org/10.1177/0300060520918087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218936/
https://www.ncbi.nlm.nih.gov/pubmed/32363958
http://dx.doi.org/10.1177/0300060520918087

Ejemplares similares